Changes in weight, body composition and metabolic parameters after switch to dolutegravir/lamivudine compared with continued treatment with dolutegravir/abacavir/lamivudine for virologically suppressed HIV infection (The AVERTAS trial): a randomised, open-label, superiority trial in Copenhagen, Denmark

Karen Brorup Heje Pedersen^*, Andreas Knudsen, Søren Møller, Hartwig Roman Siebner, Jens Dahlgaard Hove, Jan Gerstoft, Thomas Benfield

^*Corresponding author af dette arbejde

Infektionsmedicinsk Afdeling
Lungemedicinsk Afd. L
Funktions- og Billeddiagnostisk Enhed
Funktions- og Billeddiagnostisk Enhed, MR-Forskningssektionen
Hjertemedicinsk Afdeling
Afdeling for Infektionssygdomme

Fingeraftryk

Dyk ned i forskningsemnerne om 'Changes in weight, body composition and metabolic parameters after switch to dolutegravir/lamivudine compared with continued treatment with dolutegravir/abacavir/lamivudine for virologically suppressed HIV infection (The AVERTAS trial): a randomised, open-label, superiority trial in Copenhagen, Denmark'. Sammen danner de et unikt fingeraftryk.

Sorter
Vægt
Alfabetisk

Fingeraftryk

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science